JAFRAL contributes to a groundbreaking gene therapy clinical trial

We are proud to announce that JAFRAL has been GMP manufacturer in Europe’s first clinical trial of gene immunotherapy for basal cell carcinoma of the head and neck.

The Phase I trial, conducted as part of the SmartGene.si project and led by the Institute of Oncology Ljubljana, successfully demonstrated the safety and efficacy of an innovative interleukin-12 (IL-12) gene therapy. This therapy works by injecting the genetic code for IL-12 into the patient’s cells using electroporation, offering a promising new approach to cancer treatment.

JAFRAL contributed its expertise in biomanufacturing, ensuring high-quality production of the drug in accordance with Good Manufacturing Practice (GMP) standards. Our collaboration with key research and clinical partners — Institute of Oncology Ljubljana, Cobik, Iskra PIO, JAFRAL, Faculty of Electrical Engineering at the University of Ljubljana, Veterinary Faculty of the University of Ljubljana and the Clinic for Otorhinolaryngology and Cervicofacial Surgery at the University Medical Centre Ljubljana- reflects Slovenia’s active engagement in biomedical innovation.

This achievement paves the way for further advancements in gene therapy, bringing new hope to patients with challenging cancers. Continued collaboration between research institutions and industry partners will support the development of innovative treatments in clinical practice.